Cancer clinical trials advance treatment paradigms by testing agents for potentially greater efficacy or lesser toxicity. The Research Pharmacy shared resource provides expertise in investigational and commercially available cancer therapeutic agents and ensures a uniformly high standard of safe, accurate treatment for CINJ patients with cancer participating in clinical trials; these services are crucial to one of the central strategic initiatives of the cancer center: high quality, innovative translational research. The Research Pharmacy shared resource of Rutgers Cancer Institute of New Jersey (CINJ) is a Cancer Center managed shared resource whose purpose is to support CINJ members who conduct rigorously reviewed research with investigational agents in human subjects by providing an efficient, centralized service of extraordinary quality. Since the last CCSG submission, Research Pharmacy is increasingly called upon for consultation in the planning of clinical projects. CINJ investigators seek advice on issues regarding drug interactions, drug sequencing for multi-agent trials, dose modifications, formulation of compounds, identification of compounds for use, and consultations regarding Investigational New Drug (IND) applications. Additionally, our Informatics Pharmacist performs various data mining of our electronic medical record (EMR) to assist investigators in selecting and modeling clinical trials based on our patient population. These efforts are guided by policies and procedures ensuring compliance with HIPAA and institutional review board (IRB) requirements.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA072720-22
Application #
10112870
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-03-01
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
22
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Rbhs -Cancer Institute of New Jersey
Department
Type
DUNS #
078728091
City
New Brunswick
State
NJ
Country
United States
Zip Code
08901
George, Blessy; Joy, Melanie S; Aleksunes, Lauren M (2018) Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood) 243:272-282
Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821
Jian-Yu E; Graber, Judith M; Lu, Shou-En et al. (2018) Effect of Metformin and Statin Use on Survival in Pancreatic Cancer Patients: a Systematic Literature Review and Meta-analysis. Curr Med Chem 25:2595-2607
Moloughney, Joseph G; Vega-Cotto, Nicole M; Liu, Sharon et al. (2018) mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. J Biol Chem 293:16464-16478
Zhu, Sining; Jin, Juan; Gokhale, Samantha et al. (2018) Genetic Alterations of TRAF Proteins in Human Cancers. Front Immunol 9:2111
Perekatt, Ansu O; Shah, Pooja P; Cheung, Shannon et al. (2018) SMAD4 Suppresses WNT-Driven Dedifferentiation and Oncogenesis in the Differentiated Gut Epithelium. Cancer Res 78:4878-4890
Llanos, Adana A M; Tsui, Jennifer; Rotter, David et al. (2018) Factors associated with high-risk human papillomavirus test utilization and infection: a population-based study of uninsured and underinsured women. BMC Womens Health 18:162
Hadigol, Mohammad; Khiabanian, Hossein (2018) MERIT reveals the impact of genomic context on sequencing error rate in ultra-deep applications. BMC Bioinformatics 19:219
Severson, Eric A; Riedlinger, Gregory M; Connelly, Caitlin F et al. (2018) Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens. Blood 131:2501-2505
Shih, Weichung Joe; Lin, Yong (2018) Relative efficiency of precision medicine designs for clinical trials with predictive biomarkers. Stat Med 37:687-709

Showing the most recent 10 out of 775 publications